Skip to main content

Table 2 Utility Gains Adjusted for Adverse Effects

From: Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia

 

VAS

SEM

SG

SEM

Baseline

0.519

0.00725

0.712

0.00578

12 weeks

0.570*

0.00676

0.751†

0.00560

24 weeks

0.583*

0.00668

0.762†

0.00542

36 weeks

0.594*

0.00658

0.768†

0.00551

50 weeks

0.591*

0.00668

0.766†

0.00554

Endpoint

0.583*

0.00647

0.763†

0.00552

  1. VAS indicates visual analog scale; SEM, standard error of the mean; SG, standard gamble.
  2. *P < 0.001 versus baseline visual-analog-scale measurement (Wilcoxon signed rank test).
  3. † P < 0.001 versus baseline standard-gamble measurement (Wilcoxon signed rank test).
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us